Artificial Intelligence In Health Care: Benefits and Challenges of Machine Learning in Drug Development
Artificial Intelligence In Health Care: Benefits and Challenges of Machine Learning in Drug Development, Report No. GAO-20-215SP, Jan. 2020
Machine learning—a field of artificial intelligence (AI) in which software learns from data to perform a task—is already used in drug development and holds the potential to transform the field, according to stakeholders such as agency officials, industry representatives, and academic researchers. Machine learning is used throughout the drug development process and could increase its efficiency and effectiveness, decreasing the time and cost required to bring new drugs to market. These improvements could save lives and reduce suffering by getting drugs to patients in need more quickly, and could allow researchers to invest more resources in areas such as rare or orphan diseases.
Publication type:
project report
Publication language:
English
Publication date:
2020
Publication URL:
https://www.gao.gov/assets/710/703558.pdf
Institute:
Science, Technology Assessment, and Analytics team of the U.S. Government Accountability Office (GAO) (STAA)
Country:
United States of America
Project:
Artificial Intelligence In Health Care: Benefits and Challenges of Machine Learning in Drug Development (STAA)

 Back